Natco to sell Sovaldi generics following Gilead deal
India-based generic drug maker Natco Pharma has signed a non-exclusive licensing agreement with Gilead Sciences that allows Natco to make and sell generic versions of hepatitis C drugs including Sovaldi (sofosbuvir), it was announced yesterday (March 2).
If you don't have a login or your access has expired, you will need to purchase a subscription to gain access to this article, including all our online content.
For more information on individual annual subscriptions for full paid access and corporate subscription options please contact us.
To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.
For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk
16 September 2015 The Indian Pharmaceutical Alliance has dropped its opposition to a patent application filed by Gilead Sciences covering its hepatitis C drug Sovaldi.
16 September 2015 The Indian Pharmaceutical Alliance has dropped its opposition to a patent application filed by Gilead Sciences covering its hepatitis C drug Sovaldi.
16 September 2015 The Indian Pharmaceutical Alliance has dropped its opposition to a patent application filed by Gilead Sciences covering its hepatitis C drug Sovaldi.